A股異動丨捷強裝備(300875.SZ)復牌大漲14.63% 擬收購卡迪諾科技100%股權
格隆匯5月12日丨捷強裝備(300875.SZ)復牌大漲14.63%,報49.98元,總市值38億元。捷強裝備公吿,公司擬發行股份及支付現金購買卡迪諾科技100%股權並募集配套資金。其中,公司擬向全體交易對方分別以發行股份方式支付73%的交易對價,以現金方式支付27%的交易對價,最終的股份和現金的支付比例將由交易各方協商後,另行簽署補充協議明確約定。截至目前,本次交易的審計及評估工作尚未完成,標的資產估值及定價尚未確定。本次交易預計構成重大資產重組。卡迪諾科技的主營業務為核輻射檢測與監測設備以及核輻射防護的技術研究、設計開發、生產和銷售。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.